Amgen is a leading human therapeutics company in the biotechnology industry. For more than 25

years, the company has tapped the power of scientific discovery and innovation to dramatically

improve people's lives. Amgen pioneered the development of novel products based on advances in

recombinant DNA and molecular biology and launched the biotechnology industry's first blockbuster

medicines.

Originally founded in 1980 as AMGen (Applied Molecular Genetics), Amgen pioneered the development

of novel and innovative products based on advances in recombinant DNA and molecular biology. More

than a decade ago, Amgen introduced two of the first biologically derived human therapeutics,

EPOGEN® (Epoetin alfa) and NEUPOGEN® (Filgrastim). 

Today, Amgen is a Fortune 500 company whose business has expanded to serve patients around

the world in supportive cancer care and the treatment of anemia, rheumatoid arthritis, and other

autoimmune diseases such as psoriatic arthritis and ankylosing spondylitis. As a science-based and

patient-focused organization, Amgen will follow the science wherever it may lead, to best treat

serious illness. For the second time Amgen has been named one of the Sunday Times' Top 100 "Best

Companies to Work For" in the UK.